BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7315355)

  • 1. Lymphocyte cytotoxicity against autologous bladder tumor cells in humans, investigated by use of a chromium-51 release assay.
    Jacobsen F
    Acta Pathol Microbiol Scand C; 1981 Jun; 89(3):175-80. PubMed ID: 7315355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of primary tumor bed lymphocytic infiltration and peripheral lymphocyte cytotoxicity in patients with transitional cell carcinoma.
    Jones LW; O'Toole C
    Natl Cancer Inst Monogr; 1978 Dec; (49):183-5. PubMed ID: 748770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 51chromium isotope release assay for detecting cytotoxicity to human bladder carcinoma.
    O'Toole C
    Int J Cancer; 1977 Mar; 19(3):324-31. PubMed ID: 844912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
    Mizutani Y; Nio Y; Fukumoto M; Yoshida O
    Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and humoral in vitro cytotoxicity against autologous bladder tumor cells in humans. Differences in autologous cytotoxicity against non-invasive and invasive transitional-cell tumors of the urinary bladder.
    Jacobsen F
    Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):235-9. PubMed ID: 7315359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular cytotoxicity in vitro in transitional cell carcinoma of the human urinary bladder: 51Cr-release assay.
    Troye M; Perlmann P; Larsson A; Blomgren H; Johansson B
    Int J Cancer; 1977 Aug; 20(2):188-98. PubMed ID: 892930
    [No Abstract]   [Full Text] [Related]  

  • 7. Lymphocyte response to transitional cell carcinoma: peripheral cytotoxicity and local tumor infiltration.
    Jones LW; O'Toole C
    J Urol; 1977 Dec; 118(6):974-7. PubMed ID: 926279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-dependent in vitro cytotoxicity against autologous invasive bladder tumor cells in humans. Evaluation of the possible role of naturally-occurring antibodies in complement-dependent cytotoxicity.
    Jacobsen F
    Acta Pathol Microbiol Scand C; 1981 Oct; 89(5):297-302. PubMed ID: 7315361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium.
    Vilien M
    Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures.
    Troye M; Vilien M; Pape GR; Perlmann P
    Int J Cancer; 1980 Jan; 25(1):33-43. PubMed ID: 7399743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary.
    Perlmann P; Troye M; Pape G; Blomgren H; Johansson B
    Urol Res; 1978; 6(4):207-9. PubMed ID: 741533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity.
    Larsson A; Näslund I; Troye M
    Cancer Immunol Immunother; 1982; 14(2):82-5. PubMed ID: 6965230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cytotoxicity of lymphocyte subpopulations against autologous human bladder tumor cells.
    Jacobsen F
    Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):241-6. PubMed ID: 6976062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Nio Y; Yoshida O
    J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic evaluation of human bladder cancer: in vitro studies.
    Elhilali MM; Nayak SK
    Cancer; 1975 Feb; 35(2):419-31. PubMed ID: 1111918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitional cell carcinoma: lymphocyte-mediated cytotoxicity.
    Troye M; Pape GR
    Natl Cancer Inst Monogr; 1978 Dec; (49):85-7. PubMed ID: 311895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.